A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13

PURPOSE: The optimal cytotoxic regimens have not been established for patients with non-small cell lung cancer (NSCLC) who develop disease progression on first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). MATERIALS AND METHODS: We conducted a multi-center randomized ph...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res Treat
Main Authors: Yoo, Kwai Han, Lee, Su Jin, Cho, Jinhyun, Lee, Ki Hyeong, Park, Keon Uk, Kim, Ki Hwan, Cho, Eun Kyung, Choi, Yoon Hee, Kim, Hye Ryun, Kim, Hoon-Gu, Ahn, Heui June, Lee, Ha Yeon, Yun, Hwan Jung, Kang, Jin-Hyoung, Jeong, Jaeheon, Choi, Moon Young, Jung, Sin-Ho, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju
Formato: Artigo
Idioma:Inglês
Publicado em: Korean Cancer Association 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6473296/
https://ncbi.nlm.nih.gov/pubmed/30177585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2018.324
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados